IMUX Projected Dividend Yield
Immunic Inc ( NASDAQ : IMUX )Immunic, Inc. is a biotechnology company. Co. is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Co.'s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. 21 YEAR PERFORMANCE RESULTS |
IMUX Dividend History Detail IMUX Dividend News IMUX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |